Evidence for investigating GSK-3 inhibitors as potential therapeutics for severe COVID-19
- 16 March 2022
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 605, 171-176
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R15GM110602)
This publication has 33 references indexed in Scilit:
- A Phase II Trial of Tideglusib in Alzheimer's DiseaseJournal of Alzheimer’s Disease, 2015
- Lipopolysaccharide fromRhodobacter sphaeroidesAttenuates Microglia-Mediated Inflammation and Phagocytosis and Directs Regulatory T Cell ResponseInternational Journal of Inflammation, 2015
- AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humansJournal of Neurochemistry, 2013
- Signaling in Innate Immunity and InflammationCold Spring Harbor Perspectives in Biology, 2012
- Lipopolysaccharide-driven Th2 Cytokine Production in Macrophages Is Regulated by Both MyD88 and TRAMJournal of Biological Chemistry, 2009
- Heat shock proteins and immune systemJournal of Leukocyte Biology, 2009
- Toll-like receptor–mediated cytokine production is differentially regulated by glycogen synthase kinase 3Nature Immunology, 2005
- Lithium-Mediated Phosphorylation of Glycogen Synthase Kinase-3b Involves PI3 Kinase-Dependent Activation of Protein Kinase C-αJournal of Molecular Neuroscience, 2004
- The renaissance of GSK3Nature Reviews Molecular Cell Biology, 2001
- The Phosphorylation of Rabbit Skeletal Muscle Glycogen Synthase by Glycogen Synthase Kinase-2 and Adenosine-3': 5'-Monophosphate-Dependent Protein KinaseEuropean Journal of Biochemistry, 1976